UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Paul Krogstad, MD


Paul Krogstad, MD

UCLA Physician Paul Krogstad, MD specializes in Pediatric Infectious Diseases.
Pediatric Infectious Diseases
Language Spoken
Hospital Affiliation
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
State License Number
(310) 825-0867 Information and referral
(310) 794-1049 Laboratory
Voted Best Doctor
Voted Super Doctor

UCLA Children's Health Center
200 UCLA Medical Plaza, Suite 265
Los Angeles, CA 90095

Pediatric Infectious Diseases, American Board of Pediatrics, 1994, 2008
Pediatrics, American Board of Pediatrics, 1989, 2012
Pediatrics/Infectious Diseases, University of Washington Medical Center, 1987 - 1990
Pediatrics, Tulane University Hospital & Clinics, 1985 - 1987
Pediatrics, Tulane University Hospital & Clinics, 1984 - 1985
MD, Tulane University School of Medicine, 1984
Department Affiliation
Provider, Pediatric Infectious Diseases, Care-4-Families
Research Interest

HIV therapy and immunopathogenesis . 
Enterovirus disease and its treatment
Genetic basis for disseminated coccidioidomycosis

Additional Information

Clinical Expertise: 
Enterovirus infections, HIV therapy, bone and joint infections, viral myocarditis

Dr. Paul Krogstad attended UCLA and received his Bachelor of Science in Cybernetics and a Master's Degree in Engineering.  After leaving Los Angeles, he attended the Tulane University School of Medicine in New Orleans, Louisiana, where he also completed his training in Pediatrics. 

He trained as a specialist in Pediatric Infectious Diseases at the University of Washington in Seattle, then returned to UCLA for additional postdoctoral training in human retrovirology.  He joined the UCLA faculty in 1992 and is now a Professor in the departments of Pediatrics and Pharmacology, and serves as the Director of the Fellowship Program in Pediatric Infectious Diseases.

Dr. Krogstad's laboratory focuses on molecular virology and the pathogenesis of viral diseases.  His studies of HIV pathogenesis currently include evaluation of the  impact of HIV on T cell production  and immunological ontogeny in HIV infected children and adolescents.  His laboratory research also includes molecular approaches to the identification of cellular factors involved in coxsackievirus replication and the immunological and viral contributions to the pathogenesis of enteroviral myocarditis.  In addition, he has led and collaborated in several studies of new drugs for the treatment of HIV and enteroviral infection.  

Memberships, Major Commitees
Member, Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children , 2007- present

Site Investigator: Collaborative Antiviral Study Group Protocol 106.

Laboratory Research
HIV immunopathogenesis - Research conducted in 2010-2011 focused on examining perturbations of T cell receptor populations among HIV infected adolescents and adults.  Within the IMPAACT research network, I have obtained approval for a retrospective analysis of the clinical significance of persistent CD4 lymphocytopenia in children with successful suppression of HIV by antiretroviral therapy.

HIV therapy - Obtained approval from IMPAACT network to go forward with protocol development for P1101, a Phase I/II study of raltegravir as part of HAART in HIV infected children with TB coinfection. 

Enterovirus Replication and pathogenesis.  In studies being conducted by  Dr. Susan Wollersheim, we have examined the
Molecular epidemiology of picornaviruses.  Dr. Susan Wollersheim is using molecular phylogenetic methods to identify picornaviruses (enteroviruses and rhinoviruses) detected by multiplex PCR methods in the UCLA Clinical Microbiology Laboratory.  We hope to determine if the reported high frequency of detection of the nucleaic acid of rhinoviruses and human enteroviruses in respiratory virus specimens reflects dual infection or imprecision on the part of the commercial methodology being used.

Antiviral agents for enterovirus infection.  Two distinct approaches are being used in efforts to identify antiviral therapies for enterovirus infection.  In the first, we have used mass spectrometry to identify cellular proteins involved in translation of the enterovirus genome under the control of the viral Internal Ribosome Entry Site.  In the second, we are performing high throughput screeningof chemical libraries to identify inhibitors of lytic replication of enterovirus agents.

Genetic basis for disseminated coccidioidomycosis:  conducted pilot study to demonstrate utility of archived pathology specimens to as source of DNA to identify genetic polymorphisms associated with dissemination of coccidioidomycosis in African Americans.  (Presented at 55th Annual Meeting of the Coccidioidomycosis Study Group. Davis CA. April, 2011.)

Fellowship Program

Service to Hospital, Medical School, and UCLA AIDS Institute.

Member, Antimicrobial Agent Subcommittee of the UCLA Pharmacy and Therapeutics
Chair, Department of Molecular and Medical Pharmacology Committee on Merit Promotions 2010-present
Member, Department of Molecular and Medical Pharmacology Committee on Merit Promotions 2009-present
Department of Pediatrics
Member, Review and Appraisal Committee
Chair, Cardiology Chief Search Committee (2009-10)
Chair, Immunology Chief Search Committee (2011- )

Awards & Recognition
  • Tulane University nomination: AOA honor society
  • Pediatric AIDS Foundation Scholar Award
  • Robert C. Neerhout Teaching Award
  • Elizabeth Glaser Pediatric AIDS Foundation Scientist Award

Selected Publications:
(Link to my PubMed publications)

1. Rudy BJ, Kapogiannis BG, Lally MA, Gray GE, Bekker LG, Krogstad P, and McGowan I. Youth Specific Considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.  J. Acquir Immune Syndr 2010;54:S31-S42.

2. Kitchen CMR, Krogstad P, and  Kitchen SG. In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV.  The Open Medical Informatics Journal  2010; 225-232.

3. Zuo J, Church J, Belzer M, Kitchen CR, Ank B, Schmid I, and Krogstad P.  Enhanced CD8+ T Cell Apoptosis in HIV Infected Adolescents. AIDS Res Hum Retro 2010; 26:681-4.

4. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Li J, Hong PW, Aguilar HC, Grock A, Honko AN, Johnson J, Porotto M, Damoiseaux R, Miller JP, Negrete OA, Krogstad P, Moscona A, Hensley LE, Whelan SP, Holbrook MR, Jung ME, Lee B.  A novel, potent broad-spectrum antiviral targeting enveloped virus entry.  Proc Natl Acad Sci.  2010;107:3157- 62.

5. Reiff A, Krogstad P, Moore S, Shaham B, Parkman R, Kitchen C, and Weinberg K.  Study of Thymic Size and Function in Children and Adolescents with Treatment Refractory Systemic Sclerosis Eligible for Immunoablative Therapy.  Clinical Immunology 2009;133:295-302

6. Miller JP, Geng YZ, NG W, Yang OO, and Krogstad P.  Packaging Limits and Stability of HIV-1 Sequences in a Coxsackievirus B Vector.  Vaccine 2009; 27: 3992-4000.

7. Jhaveri  R, Bronstein D, Sollod J, Kitchen CR,  and Krogstad P.  Outcome of Infections with Extended Spectrum Beta-Lactamase Producing Organisms in Children. J Pediatric Infectious Diseases. 2008; 3: 229-233

8. Krogstad P, Hammon R, Halnon NJ, and Whitton JL. Fatal Neonatal Myocarditis Caused by a Recombinant Human Enterovirus-B Variant. Ped Inf. Dis J. 2008;27:668-9.

9. Kitchen CMR, Nuño M, Kitchen SG, and Krogstad PA.  Enfuvirtide antiretroviral therapy in HIV-1 infection. Ther Clin Risk Manag. 2008; 4:433-9.

10. Lee JC, Boechat MI, Belzer M, Church JA, De Ville J, Nielsen K, Weston S, Geng Y, Dunaway T, Kitchen C, and Krogstad PA.  Thymic volume, T-cell populations, and parameters of thymopoiesis in adolescent and adult survivors of HIV infection acquired in infancy. AIDS. 2006;20:667-74.

Back to top
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.

Find out how to refer a patient
Paul Krogstad, click here to update your profile.